共 160 条
[1]
Tilly H(2015)Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 26 v116-25
[2]
Gomes da Silva M(2017)Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study Blood 130 1800-1808
[3]
Vitolo U(1993)A predictive model for aggressive non-Hodgkin’s lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project N Engl J Med. 329 987-94
[4]
Jack A(2019)Early risk stratification for diffuse large B-cell lymphoma integrating interim Deauville score and international prognostic index Ann Hematol 98 2739-2748
[5]
Meignan M(2018)Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI Blood Rev 32 400-415
[6]
Lopez-Guillermo A(2014)Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group J Clin Oncol 32 3048-3058
[7]
Crump M(2011)High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma Int J Hematol 93 502-508
[8]
Neelapu SS(2014)Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma Eur J Nucl Med Mol Imaging 41 2017-2022
[9]
Farooq U(2013)Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma Cancer 119 1195-1202
[10]
Van Den Neste E(2019)PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy Eur J Nucl Med Mol Imaging 46 1468-1477